Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study

Authors

Paolo F. Caimi, Cleveland Clinic
Brad S Kahl, Washington University School of Medicine in St. Louis
et al.

Journal

Haematologica

Publication Date

4-1-2024

Volume

109

Issue

4

First Page

1184

Last Page

1193

Document Type

Open Access Publication

DOI

10.3324/haematol.2023.283459

Rights and Permissions

Caimi PF, Ai WZ, Alderuccio JP, Ardeshna KM, Hamadani M, Hess B, Kahl BS, Radford J, Solh M, Stathis A, Zinzani PL, Wang Y, Qin Y, Wang L, Xu ZC, Carlo-Stella C. Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study. Haematologica. 2024 Apr 1;109(4):1184-1193. doi: 10.3324/haematol.2023.283459. ©2024 Ferrata Storti Foundation. Published under a CC BY-NC license

Recommended Citation

Caimi, Paolo F.; Kahl, Brad S; and et al., "Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: Long-term efficacy and safety from the phase II LOTIS-2 study." Haematologica. 109, 4. 1184 - 1193. (2024).
https://digitalcommons.wustl.edu/oa_4/3696

Additional Links

Supplemental material is available for this article at publisher site.